论文部分内容阅读
苯酪肽(BT-PABA)是一种新的胰腺外分泌功能试验诊断药。口服后,在小肠被糜蛋白酶特异地裂解而释放出对氨基苯甲酸(PABA)。PABA在小肠内吸收,在肝内乙酰化,经肾排出。故测定尿中PABA含量,能简接反映胰腺外分泌功能。此法中Imo-ndi首创,称胰腺功能诊断(PFD)试验,现已被欧美和日本等学者确认为一种简易、安全和有价值的胰腺外分泌功能诊断方法。我院与上海试剂三厂共同研制了国产BTPABA,经临床试用300例,其中正常人(110例)PABA排泄率为83.86±10.77％
Benzotriptyline (BT-PABA) is a novel diagnostic test for pancreatic exocrine function. After oral administration, chymotrypsin is specifically cleaved in the small intestine to release p-aminobenzoic acid (PABA). PABA is absorbed in the small intestine, acetylated in the liver, and excreted via the kidneys. Therefore, the determination of urinary PABA content, can simply reflect pancreatic exocrine function. This method Imo-ndi pioneered, said pancreatic function test (PFD) test, has now been Europe, the United States and Japan and other scholars confirmed as a simple, safe and valuable diagnostic method of pancreatic exocrine function. Our hospital and Shanghai Reagent Factory co-developed a domestic BTPABA, clinical trial of 300 cases, of which normal (110 cases) PABA excretion rate of 83.86 ± 10.77%